FAO [1985], OEDC [1986],izgotvile nasoki koi sozdavaat osnova za sigurna upotreba napestitsidite i drugite khemikalii.Na ovoj nachin vo site tsivilizirani zemji vo svetot se nastojuva dase kontrolira proizvodstvoto, prometot i koristenjeto napestitsidite i da se nadminat ili svedat na minimum eventualniteposleditsi od primena na ovie khemikalii.Tselta na ovoj trud e opredeluvanje na kontsentratsijata naperzistentni organokhlorni pestitsidi vo reki i povrshinski vodivo Prespanskiot Region, preku razrabotka na metoda zaopredeluvanje na organokhlorni pestitsidi koja mozhe da se koristiza rutinska analiza vo sekojdnevnata laboratoriska praktika.Opredeluvanjeto na sodrzhinata na organokhlorni pestitsidi eizvrsheno vo nad 80 razlichni primerotsi na povrshinski vodi oddevet lokaliteti vo Prespanskiot Region: (1) Selo Stenje;(2)Turistichka naselba Pretor; (3) Turistichka naselba Oteshevo; (4)Plazha Slivnitsa; (5) Turistichka naselba Krani; (6) Selo D. Dupeni;(7) Golema Reka; (8) Brajchinska Reka; (9) Kranska Reka.Opredeluvanjeto na organokhlornite pestitsidi vo povrshinskitevodi e napraveno spored metoda EPA 508 - Metoda za simultanoopredeluvanje na povekje organokhlorni pestitsidi vo voda so gasenkhromatograf i ECD detektor.Multirezidualnite metodi kako i metodite za opredeluvanje narezidui na samo eden pestitsid opfakjaat nekolku osnovni fazi:ekstraktsija na pestitsidot od matriksot na primerokot;prechistuvanje dokolku e potrebno, za da se otstranatinterfererirachkite koekstraktanti; razdvojuvanje na analitot odostanatite komponenti, voobichaeno so GC ili HPLC;kvantifikatsija preku sporeduvanje na odgovorot na primerokot soodgovorot na standardite; potvrda na rezultatite so primena nanekoja pomoshna metoda.Dobienite vrednosti za kontsentratsiite na ispituvanitepestitsidi pokazhaa razlichna zastapenost vo primerotsite.Pestitsidite Lindan, p,p'DDT, p,p'DDD, p,p'DDE, Aldrin se prisutni voskoro site primerotsi.Endosulfan I i II, Endrin, Dieldrin, se zastapeni vo okolu polovina odispituvanite primerotsi, dodeka Heptachlor, Heptachloe epoksid iMetoksichlor se zastapeni vo znachitelno pomal broj na primerotsi.Vo odnos na kontsentratsijata na poedinite vidovi na organokhlornipestitsidi, spored Uredbata za klasifikatsija na vodite, ne eopredelena vrednost nad maksimalno dolzvolenata kontsentratsijavo nitu eden primerok. Sepak, spored utvrdenata kontsentratsija,mozhe da se napravi gradatsija na povrshinskite vodi od II do IV. Vrzosnova na kontsentratsijata na organokhlornite pestitsidi voispituvanite mesetsi, mozhe da se zakluchi deka najzagaden elokalitetot 7 (Golema Reka), a najnezagadeni se lokalitetite: (1)Selo Stenje i (6) selo D. Dupeni. Vo 53% od analiziraniteprimerotsiutvrdeno e prisustvo na p,p'DDT. Odnosot pomegju p,p'DDEi p,p'DDD ukazhuvaat na perzistentnosta na pestitsidot p,p'DDT.Vrz osnova na dobienite rezultati potrebno e da se prevzematsoodvetni merki, kako i organichena primena na pestitsidite voperiodot kogase ochekuva nivna najvisoka kontsentratsija.LITERATURA1. Ahad K., Ahmed I., Muhhemmed, Aziz S., U.K.Baloach, Determination ofpesticodes residues in groud water of Mardan devision, Pakistan.J.water (SouthAfrika);26(3)409-412,20002. Darko G., Akato O., Oppong C., Persistent organochlorine pesticides residues infish, sediment and water from Lake Bosomtwi, Chana, Chemosphere.2008 May;72(1):21-4 Epub 2008 Apr 73. Kasozi.G.N, Kiremire B.T., Budenyi F.W.B., Kirsch N.H., Organohlorine Residues inwater and fish samples from Lake Viktoria, Jouran of Chromatography Uganda,20064. Nardeli V., Palmero C., Centoze C., Journal of Cromatography A 1034-33, 20045. Sorensen, R.B., Bruggemann L., Carisen L., Mogensen B.B, Kreuger J., Pundez S.,Analysis of monitoring data of pesticide residues in surface water. EnvironmentalToxicol. Chem. ; 22(3); 661-670,2003LABORATORY BIOMARKERS IN CARDIOVASCULAR MEDICINE Hiljadnikova Bajro M., Kadifkova Panovska T.Faculty of Pharmacy, University "Ss. Cyril and Methodius", Skopje, Re-public of MacedoniaCardiovascular diseases (CVDs) are the leading cause of disability anddeath in industrialized world and most of the developing countries.Hence, evaluation of cardiovascular risk factors in the population, earlydiagnosis of the disease and appropriate therapeutic managementare becoming excessively attractive healthcare issue increasing the in-terest for development of new biomarkers of CVD(1).An ideal biomarker should comply many pre-analytical, analytical andpost-analytical criteria, including in vivo and in vitro stability, analyti-cal sensitivity, reproducibility and accuracy, easy performance, inter-national standardization, favorable cost-benefit ratio, good diagnosticand prognostic accuracy, low biological variation with strictly definedreference range, and good acceptance by the patient. The primary fea-ture of a good marker is enhancing the clinician's ability to managethe patient in an optimal manner (2), but biomarkers should be ac-cepted in the clinical practice only if possessing efficiency and effec-tiveness according to EBLM principles (3)Until now, only several markers apart from the classic risk factors suchas dyslipidemia, insulin resistance, diabetes and estrogenous status,have proved clinical utility to be applied in regular clinical practice.Cardiac specific troponins are current standard biomarkers in diag-nosing acute myocardial infarction and risk stratification of patientswith acute coronary syndromes. Brain-type natriuretic peptides aidthe diagnosis of acute and chronic heart failure, have proved prog-nostic value and might help in targeting therapies. Large trials haveconfirmed the prognostic impact of C-reactive protein and its role inidentification of healthy individuals who could benefit from intensivestatin therapy. Creatine phosphokinase MB is a marker with well es-tablished prognostic, diagnostic and therapeutic value. Exclusion ofdeep vein thrombosis and pulmonary embolism is assisted by D-dimertesting. Myeloperoxidase, lipoprotein-associated phospholipase A2, In-terleukin-6, matrix-metalloproteinase-9, copeptin, growth differenti-tation factor are only a few of the many biomarkers emerging with apotential of clinical utility (4,5).Application of molecular biology techniques in identification of car-diovascular biomarkers is becoming interesting but is mostly limiteddue to the multifactor etiology of the CVDs involving environmentaland behavioral impact on the genetic background. Still, early researchhas resulted in identifying main genes associated with the familial car-diomyopathies and arrhythmias, and genes described in association137Macedonian Pharmaceutical Bulletin 57 (suppl), 2011CLINICAL BIOCHEMISTRY / TOXICOLOGY / FOOD AND NUTRITION oral presentationsFIFTH CONGRESS OF PHARMACY OF MACEDONIA WITH INTERNATIONAL PARTICIPATIONwith an increased risk of cardiovascular disease. Further to this themultifactor etiology of these diseases urges the need of establishinga genomic/proteomic profile associated with a CVD instead of singlelocus genetic analysis (6). Serious efforts are made towards application of mass spectrometryfor identification of proteins/processes as biomarkers of CVDs, anddevelopment of new markers in this field are expected soon (7).In conclusion, until recently the clinical cardiologists could choosefrom a very few short list of non-specific laboratory tests in manage-ment of patients with CVD. The continuous progress in developmentof new assays including molecular biology and genetic tests, has im-proved both, the diagnostic accuracy and the prognostic stratificationof patients as well as the patient outcome. Still, there is much to gountil discovery of an "ideal" cardiovascular biomarker, if possible at all.REFERENCES1. Jaffe AS, Babuin L, Apple FS. Biomarkers in acute cardiac disease: the presentand the future. J Am Coll Cardiol. 2006 Jul 4;48(1):1-11. Epub 2006 Jun 12.2. Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practicalconsiderations. Circulation. 2006 May 16;113(19):2335-62.3. Marshall DA, O'Brien BJ. Economic evaluation of diagnostic tests. In: Price PC,Christensen RH, editors. Evidence-based laboratory medicine - from principles tooutcomes. Washington DC: Hochholzer W, Morrow DA, Giugliano RP. Novelbiomarkers in cardiovascular disease: update 2010. Am Heart J. 2010Oct;160(4):583-944. Sundstrom J. Myocardial biomarkers for prediction of cardiovascular disease. DisMarkers. 2009;26(5-6):235-46.5. Hochholzer W, Morrow DA, Giugliano RP. Novel biomarkers in cardiovasculardisease: update 2010. Am Heart J. 2010 Oct;160(4):583-946. Vittorini S, Clerico A.Cardiovascular biomarkers: increasing impact of laboratorymedicine in cardiology practice. Clin Chem Lab Med. 2008;46(6):748-63.7. Suzuki T. Cardiovascular diagnostic biomarkers: the past, present and future.Circ J. 2009 May;73(5):806-9. Epub 2009 Mar 27.LABORATORISKI BIOMARKERI VOKARDIOVASKULARNATA MEDITsINAKhiljadnikova Bajro M., Kadifkova Panovska T. Farmatsevtski Fakultet, Univerzitet "Sv. Kiril i Metodij" Skopje,Republika MakedonijaKardiovaskularnite zaboluvanja (KVZ) se glavna prichina za smrt iinvaliditet vo industrijaliziraniot svet i povekjeto od zemjite vorazvoj. Ottuka, evaluatsijata na kardiovaskularnite rizik faktorikaj populatsijata, rana dijagnoza i soodveten terapevtski tretmanna KVZ stanuvaat osobeno atraktiven zdravstven predizvikzgolemuvajki go interesot za razvoj na novi biomarkeri za KVZ (1).Idealen biomarker treba da ispolnuva brojni pred-analitichki,analitichki i post-analitichki kriteriumi, vkluchuvajki stabilnostvo in vivo i in vitro uslovi, analitichka senzitivnost, reproduts i bi -l nost i tochnost, lesna izvedba, internatsionalna stan dar d i zi ra -nost, povolen soodnos megju tsenata i poleznosta, dobra dija gno-sti chka i prognostichka pretsiznost, niska bioloshka varij a b i l nostso tochno definiran referenten interval i dobra pri fatenostod strana na patsientite. Primarna karakteristika na dobarmarker e proshiruvanje na mozhnostite na klinicharot za optimalentretman na patsientite (2), sepak biomarkerite treba da bidatprifateni vo klinichkata praksa samo dokolku poseduvaatefikasnost i efektivnost spored printsipite na laboratoriskameditsina bazirana na dokazi (3).Osven klasichnite rizik faktori kako dislipidemija, insulin-rezistentsija, diabetes mellitus i estrogenskiot status, do denessamo nekolku markeri ja dokazhale svojata klinichka efikasnostza da najdat primena vo redovnata klinichka praksa. Kardijalnitespetsifichni troponini vo momentot se standardni biomarkeri zadijagnoza na akuten miokarden infarkt i subklasifikatsija napatsientite so akutni koronarni sindromi Natriuretichnitepeptidi od mozochen tip asistiraat vo dijagnostitsiranje na akutnai khronichna srtseva slabost, imaat potvrdeno prognostichko znachenjei mozhe da pomognat vo targetiranje na terapijata. Obemni studiigo imaat potvrdeno prognostichkoto znachenje na Ts-reaktivniotprotein i negovata uloga vo identifikatsija na zdravi individuikoi bi imale korist od intenzivna terapija so statini. Kreatinfosfokinazata MB pretstavuva marker so dobro definiranaprognostichka, dijagnostichka i terapevtska vrednost. Testot za D-dimeri pomaga vo iskluchuvanje na dlaboka venska tromboza ipulmonalna embolija. Mieloperoksidazata, lipoprotein-asotsiranata fosfolipaza A2, Interleukin-6, matriks-metaloproteinazata -9, kopeptinot, i faktorot za diferentsijatsijana rast se samo nekolku od mnogute biomarkeri koi se pojavuvaatso potentsijal za klinichka upotreba (4,5).Vo identifikatsija na novi kardiovaskularni markeri, sepointeresna stanuva aplikatsijata na tekhniki od molekulkarnatabiologija, no taa e voglavno limitirana od multifaktorijalnataetiologija na KVZ koja vkluchuva vlijanie na nadvoreshnata sredinai zhivotnite naviki vrz genetskata predispozitsija. Sepak,initsijalnite istrazhuvanja dosega uspeaa da gi identifikuvaatglavnite geni povrzani so familijarnite kardiomiopatii iaritmii, kako i genite povrzani so zgolemen rizik za kardio -vaskularna bolest. Pokraj ova, multifaktorijalnata etiologija naovie zaboluvanja ja nametnuva potrebata od definiranje nagenomskiot/proteomskiot profil karakte ri sti chen za KVZ namestoednostavnata genetska analiza na poedinechni lokusi (6).Seriozni napori se vlozhuvaat vo aplikatsija na masenataspektrometrija za identifikatsija na proteini/protsesi kakobiomarkeri za KVZ i naskoro se ochekuva voveduvanje na novimarkeri vo ovaa oblast (7). Mozhe da se zakluchi deka se do neodamna klinichkite kardioloziimaa na raspolaganje mnogu mal izbor na nespetsifichnilaboratoriski testovi za tretman na patsienti so KVZ.Kontinuiraniot napredok vo razvoj na novi testovi vkluchuvajki gimolekularnite i genetskite testovi ja usovrshi dijagnostichkatapretsiznost, ovozmozhi prognostichka subklasifikatsija napatsientite i pridonese za podobruvanje na klinichkiot iskhod kajovie zaboluvanja.